Stay updated on Combining Rebastinib with Carboplatin in Advanced Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Combining Rebastinib with Carboplatin in Advanced Solid Tumors Clinical Trial page.

Latest updates to the Combining Rebastinib with Carboplatin in Advanced Solid Tumors Clinical Trial page
- ChecktodayChange DetectedThe ClinicalTrials.gov footer revision identifier changed from v3.8.0 to v3.8.1.SummaryDifference0.0%

- Check8 days agoChange DetectedThe ClinicalTrials.gov record for the rebastinib–carboplatin study is now available, with study design, eligibility, locations, outcomes, and documents. It indicates that the study is terminated and no longer recruiting participants.SummaryDifference74%

- Check15 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2. The study record still shows a 403 Forbidden error.SummaryDifference0.2%

- Check29 days agoChange DetectedA sitewide NIH transition notice appears above the study page, which still shows a 403 error instead of the study record. The site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check43 days agoChange DetectedThe revision identifier in the footer changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check50 days agoChange DetectedThe page now displays a 403 Forbidden error page, replacing the expected study record content and leaving the standard header and footer visible.SummaryDifference0.5%

Stay in the know with updates to Combining Rebastinib with Carboplatin in Advanced Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combining Rebastinib with Carboplatin in Advanced Solid Tumors Clinical Trial page.